Selskabets formål er at udvikle lægemidler til medicinsk behandling af atrieflimmer.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | - | -43 mio. | 116.1 mio. | 89.6 mio. | - | |
CVR: 34083738
Novo Holdings A/S registered with 33% ownership
registered with 20% ownership
registered with 15% ownership
registered with 5% ownership
Companies in the same industry and area
CVR 40766383
CVR 34688605
CVR 44504332
CVR 43917897
CVR 41997907
companydata.dk